Abstract: The present invention is directed to crystalline addition salts of (i) 8-hydroxyquinolin-2(1H)-one derivatives and (ii) a dicarboxylic acid or a sulfimide, or a pharmaceutically acceptable solvates thereof.
Type:
Grant
Filed:
July 24, 2014
Date of Patent:
February 28, 2017
Assignee:
Almirall, S.A.
Inventors:
Montserrat Julia Jane, Francesc Carrera Carrera, Maria Prat Quiñones, Carlos Puig Duran, Francesca Pajuelo Lorenzo, Juan Antonio Perez Andres
Abstract: The present invention is directed to crystalline addition salts of (i) 8-hydroxyquinolin-2(1H)-one derivatives and (ii) a hydroxycarboxylic acid, a sulfonic acid or a sulfimide, or a pharmaceutically acceptable solvates thereof.
Type:
Grant
Filed:
February 27, 2014
Date of Patent:
February 7, 2017
Assignee:
Almirall, S.A.
Inventors:
Montserrat Julia Jane, Francesc Carrera Carrera, Maria Prat Quiñones, Carlos Puig Duran, Francesca Pajuelo Lorenzo, Juan Antonio Perez Andres
Abstract: The present invention relates to novel compounds having ?2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.
Type:
Grant
Filed:
December 2, 2015
Date of Patent:
January 24, 2017
Assignee:
Almirall, S.A.
Inventors:
Jose Aiguade Bosch, Silvia Gual Roig, Maria Prat Quinones, Carlos Puig Duran
Abstract: The present invention relates to novel compounds having ?2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.
Type:
Grant
Filed:
December 17, 2013
Date of Patent:
December 13, 2016
Assignee:
Almirall, S.A.
Inventors:
Laia Sole Feu, Ines Carranco Moruno, Jose Aiguade Bosch, Carlos Puig Duran, Silvia Fonquerna Pou
Abstract: Pharmaceutical compositions are described comprising (a) dimethyl fumarate, (b) a diluent selected from monosaccharides, disaccharides, starch, and starch derivatives, calcium and magnesium inorganic salts, sugar alcohols, and mixtures thereof, (c) microcrystalline cellulose and (d) croscarmellose sodium, wherein the dimethyl fumarate is not covered with a gastro-resistant coating. These compositions are intended for the treatment of some inflammatory autoimmune diseases or disorders.
Type:
Application
Filed:
December 5, 2014
Publication date:
October 27, 2016
Applicant:
Almirall, S.A.
Inventors:
Maria PLANELLS JIMENEZ, Begoña DUARTE LOPEZ, Pere GUIRO COLL
Abstract: New pyrrolotriazinone derivatives having the chemical structure of Formula (I) are disclosed; as well as process for theft preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositide 3-Kinases (PI3Ks).
Type:
Grant
Filed:
October 15, 2013
Date of Patent:
July 12, 2016
Assignee:
Almirall, S.A.
Inventors:
Montserrat Erra Sola, Marta Carrascal Riera, Joan Taltavull Moll, Juan Francisco Caturla Javaloyes, Francisco Javier Bernal Anchuela, Lluis Miquel Pages Santacana, Marta Mir Cepeda, Gaspar Casals Coll, Maria Begoña Hernandez Olasagarre
Abstract: The present invention is directed to novel polymorphic crystal forms of a 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, heminapadisylate. The invention is also directed to pharmaceutical compositions comprising said polymorphic crystal forms, methods of using them to treat respiratory diseases associated with ?2 adrenergic receptor activity and a process for preparing such polymorphic crystal forms.
Type:
Grant
Filed:
March 15, 2013
Date of Patent:
May 24, 2016
Assignee:
Almirall, S.A.
Inventors:
Gemma Amat Mestres, Elvira Balaguer Ardanuy, Francesc Carrera Carrera, Iolanda Marchueta Hereu, Enrique Moyes Valls
Abstract: New pyrrolotriazinone derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositide 3-Kinases (PI3Ks).
Type:
Grant
Filed:
April 26, 2012
Date of Patent:
May 17, 2016
Assignee:
Almirall, S.A.
Inventors:
Francisco Javier Bernal Anchuela, Marta Carrascal Riera, Juan Francisco Caturla Javaloyes, Jordi Gracia Ferrer, Victor Giulio Matassa, Emma Terricabras Belart, Joan Taltavull Moll, Montserrat Erra Sola
Abstract: Provided is a powder inhalant comprising 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane wherein an anion X? is associated with the positive charge of the nitrogen atom and wherein X? is a pharmaceutically acceptable anion of a mono- or polyvalent acid.
Type:
Grant
Filed:
May 14, 2015
Date of Patent:
May 10, 2016
Assignee:
ALMIRALL, S.A.
Inventors:
Maria Dolors Fernandez Forner, Maria Prat Quinones, Maria Antonia Buil Albero
Abstract: The present disclosure relates to novel compounds having ?2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.
Type:
Grant
Filed:
May 13, 2011
Date of Patent:
April 19, 2016
Assignee:
Almirall, S.A.
Inventors:
Maria Prat Quinones, Silvia Fonquerna Pou, Carlos Puig Duran, Wenceslao Lumeras Amador, Jose Aiguade Bosch, Juan Francisco Caturla Jovaloyes
Abstract: The present disclosure relates to pharmaceutical compositions for inhalation comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, providing a metered nominal dose of aclidinium equivalent to about 200 micrograms aclidinium bromide.
Type:
Grant
Filed:
November 9, 2012
Date of Patent:
February 9, 2016
Assignee:
Almirall, S.A.
Inventors:
Rosa Lamarca Casado, Gonzalo De Miquel Serra
Abstract: The present invention relates to novel compounds having ?2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.
Type:
Grant
Filed:
November 9, 2012
Date of Patent:
January 12, 2016
Assignee:
ALMIRALL, S.A.
Inventors:
Jose Aiguade Bosch, Silvia Gual Roig, Maria Prat Quinones, Carlos Puig Duran
Abstract: New pyrazole derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).
Type:
Grant
Filed:
February 18, 2011
Date of Patent:
December 8, 2015
Assignee:
ALMIRALL, S.A.
Inventors:
Jordi Bach Taña, Lluis Miquel Pages Santacana, Joan Taltavull Moll, Paul Robert Eastwood, Jacob Gonzalez Rodrigues, Victor Giulio Matassa
Abstract: New imidazo[1,2-b]pyridazine and imidazo[4,5-b]pyridine derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).
Type:
Grant
Filed:
November 24, 2011
Date of Patent:
September 15, 2015
Assignee:
Almirall, S.A.
Inventors:
Jacob Gonzalez Rodriguez, Bernat Vidal Juan, Laura Vidal Gispert, Jordi Bach Taña
Abstract: The present invention is concerned with a process for preparing 5-(2{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one or a pharmaceutically acceptable salt thereof.
Abstract: Provided is a powder inhalant comprising 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide and methods of using the same.
Type:
Grant
Filed:
June 20, 2014
Date of Patent:
June 16, 2015
Assignee:
ALMIRALL, S.A.
Inventors:
Maria Dolors Fernandez Forner, Maria Prat Quinones, Maria Antonia Buil Albero
Abstract: New pyridin-2(1H)-one derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).
Type:
Grant
Filed:
July 23, 2012
Date of Patent:
May 19, 2015
Assignee:
ALMIRALL, S.A.
Inventors:
Paul Robert Eastwood, Jordi Bach Taña, Lluis Miquel Pages Santacana
Abstract: The invention provides methods of inhalation treatment of a respiratory disease or condition in a patient in need to such treatment without producing in said patient systemic antimuscarinic effects, comprising administering to said patient an effective amount of aclidinium.
Abstract: The present invention is concerned with a process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one or a pharmaceutically acceptable salt thereof.
Abstract: The invention relates to an inhalation device for powdered drugs to be received by a patient by an inhalation-caused air stream, comprising at least one powder reservoir, metering means for repeatedly metering a powder dose from the reservoir, a transportation mechanism for moving said metering means from a filling position for receiving a powder dose into an emptying position for releasing said powder dose into a powder channel, at least one activating device for manual operation by the patient, said activating device being operatively connected to said transportation mechanism such that upon operation a single powder dose is being metered, said activating device comprising a dosage key (5) acting on said transportation mechanism when pressed by the patient.
Type:
Application
Filed:
January 17, 2013
Publication date:
January 1, 2015
Applicant:
Almirall, S.A.
Inventors:
Martin Herder, Gerhard Ludanek, Ingo Mett, Joachim Schmidt